Form 8-K · Current Report · Filed 2025-05-01
Hologic Reports Q2 FY2025 Financial Results, Adjusts Guidance
Hologic, Inc. announced its financial results for the second quarter of fiscal 2025 on May 1, 2025, reporting a slight decrease in GAAP EPS driven by impairment charges on intangible assets, while non-GAAP EPS met guidance at $1.03. The company also slightly lowered its guidance for GAAP and non-GAAP EPS for the full fiscal year due to tariffs and geopolitical conditions. Revenue for Q2 was $1,005.3 million, slightly below the high end of guidance, and the company repurchased 3.0 million shares for $200 million in the quarter.
- Filer
- Hologic Inc. HOLX · NASDAQ
- Filed
- Accession
- 0001140361-25-016906
- CIK
- 0000859737
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$58.20
Next session
-6.9%
Since filing
+30.6%
Latest close
$76.01
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HOLX reporting the same item, with the next session's move:
Exhibits (1)
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Never miss another HOLX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.